Posted by Michael Wonder on 12 Jun 2023
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
12 June 2023 - One-third of the new active substances approved in the United States and Europe between 2016 and 2020 had not been submitted for Health Canada review by February 2023.
However, more than three-quarters of the new active substances not submitted for review would have joined 6 or more similar drugs marketed in the same therapeutic class in Canada.
